MedTrace Logo

Efficacy and Safety Study of Ingavirin® 90 mg Once Daily to Treat Influenza and Other Acute Viral Infections in Adults

NCT03154515 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 445

Last updated 2017-05-16

No results posted yet for this study

Summary

The purpose of this study is to determine whether Ingavirin® 90 mg once daily is effective and safe for the treatment of influenza and other laboratory confirmed acute respiratory viral infections in the course of standard therapy in patients 18-60 years old.

Conditions

  • Common Cold
  • Influenza, Human
  • Acute Respiratory Infection

Interventions

DRUG

Ingavirin

DRUG

Placebo

Sponsors & Collaborators

  • Valenta Pharm JSC

    lead INDUSTRY

Principal Investigators

  • Ekaterina Zakharova, MD, PhD · Valenta Pharm JSC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-01-31
Primary Completion
2014-04-30
Completion
2014-10-31

Countries

  • Russia

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03154515 on ClinicalTrials.gov